Study reveals complex role of polyploidy in cancer and treatment resistance

John­son & John­son’s Janssen on Fri­day earned an FDA ap­proval for its can­cer drug Ry­bre­vant (ami­van­tam­ab-vmjw) for the first-line treat­ment of lo­cal­ly ad­vanced or metasta­t­ic

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes